Haploidentical related umbilical cord blood stem cell transplant in a child with acute non-lymphocytic leukemia

H. M. Katzenstein, Elaine R Morgan, M. Olsewski, K. Danner-Koptik, Morris Kletzel*

*Corresponding author for this work

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Umbilical cord blood stem cells (UCBSC) were used to reconstitute hematopoiesis following myeloablative therapy in a 13-month-old infant with acute nonlymphocytic leukemia (ANLL):FAB-M5 who had failed to sustain a chemotherapeutic remission. The patient's mother was 18 weeks pregnant with her second child at the time of diagnosis. Amniocentesis revealed that the fetus was HLA-haploidentical with the patient at the paternally inherited allele. The umbilical cord blood was harvested and processed by Ficoll centrifugation with 100% recovery of 5 x 107 mononuclear cells/kg and then cryopreserved. Two weeks after collection the cells were thawed and then infused into the patient following conditioning with total body irradiation, cyclophosphamide, and etoposide. Graft-versus-host-disease (GVHD) prophylaxis consisted of cyclosporine and methotrexate. The patient experienced clinical grade I GVHD consisting of skin involvement only that resolved within 2 weeks following the addition of corticosteroids. Engraftment was achieved with an absolute neutrophil count (ANC) above 0.5 x 109/I on day 16, a platelet count above 50 x 109/1 on day 56, platelet transfusion independence on day 32 and red blood cell transfusion independence after day 44. Three months following transplantation restriction fragment length polymorphisms (RFLP) revealed no discernible difference between the donor and the recipient. The patient remains in remission without evidence of GVHD 23 months post-transplant.

Original languageEnglish (US)
Pages (from-to)765-769
Number of pages5
JournalBone Marrow Transplantation
Volume19
Issue number8
DOIs
StatePublished - Apr 2 1997

Fingerprint

Fetal Blood
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Blood Cells
Stem Cells
Transplants
Graft vs Host Disease
Erythrocyte Transfusion
Ficoll
Platelet Transfusion
Amniocentesis
Whole-Body Irradiation
Hematopoiesis
Etoposide
Platelet Count
Centrifugation
Acute Myeloid Leukemia
Methotrexate
Restriction Fragment Length Polymorphisms
Cyclophosphamide
Cyclosporine

Keywords

  • Cord blood
  • Haploidentical related
  • Leukemia
  • Transplantatation

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

@article{1c49b297d5524b16928eab3355e3987e,
title = "Haploidentical related umbilical cord blood stem cell transplant in a child with acute non-lymphocytic leukemia",
abstract = "Umbilical cord blood stem cells (UCBSC) were used to reconstitute hematopoiesis following myeloablative therapy in a 13-month-old infant with acute nonlymphocytic leukemia (ANLL):FAB-M5 who had failed to sustain a chemotherapeutic remission. The patient's mother was 18 weeks pregnant with her second child at the time of diagnosis. Amniocentesis revealed that the fetus was HLA-haploidentical with the patient at the paternally inherited allele. The umbilical cord blood was harvested and processed by Ficoll centrifugation with 100{\%} recovery of 5 x 107 mononuclear cells/kg and then cryopreserved. Two weeks after collection the cells were thawed and then infused into the patient following conditioning with total body irradiation, cyclophosphamide, and etoposide. Graft-versus-host-disease (GVHD) prophylaxis consisted of cyclosporine and methotrexate. The patient experienced clinical grade I GVHD consisting of skin involvement only that resolved within 2 weeks following the addition of corticosteroids. Engraftment was achieved with an absolute neutrophil count (ANC) above 0.5 x 109/I on day 16, a platelet count above 50 x 109/1 on day 56, platelet transfusion independence on day 32 and red blood cell transfusion independence after day 44. Three months following transplantation restriction fragment length polymorphisms (RFLP) revealed no discernible difference between the donor and the recipient. The patient remains in remission without evidence of GVHD 23 months post-transplant.",
keywords = "Cord blood, Haploidentical related, Leukemia, Transplantatation",
author = "Katzenstein, {H. M.} and Morgan, {Elaine R} and M. Olsewski and K. Danner-Koptik and Morris Kletzel",
year = "1997",
month = "4",
day = "2",
doi = "10.1038/sj.bmt.1700751",
language = "English (US)",
volume = "19",
pages = "765--769",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "8",

}

Haploidentical related umbilical cord blood stem cell transplant in a child with acute non-lymphocytic leukemia. / Katzenstein, H. M.; Morgan, Elaine R; Olsewski, M.; Danner-Koptik, K.; Kletzel, Morris.

In: Bone Marrow Transplantation, Vol. 19, No. 8, 02.04.1997, p. 765-769.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Haploidentical related umbilical cord blood stem cell transplant in a child with acute non-lymphocytic leukemia

AU - Katzenstein, H. M.

AU - Morgan, Elaine R

AU - Olsewski, M.

AU - Danner-Koptik, K.

AU - Kletzel, Morris

PY - 1997/4/2

Y1 - 1997/4/2

N2 - Umbilical cord blood stem cells (UCBSC) were used to reconstitute hematopoiesis following myeloablative therapy in a 13-month-old infant with acute nonlymphocytic leukemia (ANLL):FAB-M5 who had failed to sustain a chemotherapeutic remission. The patient's mother was 18 weeks pregnant with her second child at the time of diagnosis. Amniocentesis revealed that the fetus was HLA-haploidentical with the patient at the paternally inherited allele. The umbilical cord blood was harvested and processed by Ficoll centrifugation with 100% recovery of 5 x 107 mononuclear cells/kg and then cryopreserved. Two weeks after collection the cells were thawed and then infused into the patient following conditioning with total body irradiation, cyclophosphamide, and etoposide. Graft-versus-host-disease (GVHD) prophylaxis consisted of cyclosporine and methotrexate. The patient experienced clinical grade I GVHD consisting of skin involvement only that resolved within 2 weeks following the addition of corticosteroids. Engraftment was achieved with an absolute neutrophil count (ANC) above 0.5 x 109/I on day 16, a platelet count above 50 x 109/1 on day 56, platelet transfusion independence on day 32 and red blood cell transfusion independence after day 44. Three months following transplantation restriction fragment length polymorphisms (RFLP) revealed no discernible difference between the donor and the recipient. The patient remains in remission without evidence of GVHD 23 months post-transplant.

AB - Umbilical cord blood stem cells (UCBSC) were used to reconstitute hematopoiesis following myeloablative therapy in a 13-month-old infant with acute nonlymphocytic leukemia (ANLL):FAB-M5 who had failed to sustain a chemotherapeutic remission. The patient's mother was 18 weeks pregnant with her second child at the time of diagnosis. Amniocentesis revealed that the fetus was HLA-haploidentical with the patient at the paternally inherited allele. The umbilical cord blood was harvested and processed by Ficoll centrifugation with 100% recovery of 5 x 107 mononuclear cells/kg and then cryopreserved. Two weeks after collection the cells were thawed and then infused into the patient following conditioning with total body irradiation, cyclophosphamide, and etoposide. Graft-versus-host-disease (GVHD) prophylaxis consisted of cyclosporine and methotrexate. The patient experienced clinical grade I GVHD consisting of skin involvement only that resolved within 2 weeks following the addition of corticosteroids. Engraftment was achieved with an absolute neutrophil count (ANC) above 0.5 x 109/I on day 16, a platelet count above 50 x 109/1 on day 56, platelet transfusion independence on day 32 and red blood cell transfusion independence after day 44. Three months following transplantation restriction fragment length polymorphisms (RFLP) revealed no discernible difference between the donor and the recipient. The patient remains in remission without evidence of GVHD 23 months post-transplant.

KW - Cord blood

KW - Haploidentical related

KW - Leukemia

KW - Transplantatation

UR - http://www.scopus.com/inward/record.url?scp=0030976952&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030976952&partnerID=8YFLogxK

U2 - 10.1038/sj.bmt.1700751

DO - 10.1038/sj.bmt.1700751

M3 - Article

C2 - 9134166

AN - SCOPUS:0030976952

VL - 19

SP - 765

EP - 769

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 8

ER -